Tapentadol and Oxycodone/Naloxone Prescribing Patterns in Primary Health Care in Catalonia, Spain: A Cross-Sectional Study

References

• Treede R-D, Rief W, Barke A, et al. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the International Classification of Diseases (ICD-11). Pain. 2019;160(1):19–27. doi:10.1097/j.pain.0000000000001384
   PubMed Web of Science ®Google Scholar
• Goldberg DS, McGee SJ. Pain as a global public health priority. BMC Public Health. 2011;11:770.
   PubMed Web of Science ®Google Scholar
• International Association for the Study of Pain (IASP). European Federation of IASP Chapters. Right to pain relief. 4A. Unrelieved pain is a major global healthcare problem; 2004. Available from: https://www.iasp-pain.org/GlobalYear/RighttoPainRelief. Accessed April 20, 2021.
   Google Scholar
• Dahlhamer J, Lucas J, Zelaya C, et al. Prevalence of chronic pain and high impact chronic pain among adults – United States, 2016. MMWR. 2018;67(36):1001–1006.
   PubMed Web of Science ®Google Scholar
• Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287–333.
   PubMed Web of Science ®Google Scholar
• Dueñas M, Salazar A, Ojeda B, et al. A nationwide study of chronic pain prevalence in the general Spanish population: identifying clinical subgroups through cluster analysis. Pain Med. 2015;16(4):811–822.
   PubMed Web of Science ®Google Scholar
• Provenzano DA, Viscusi ER. Rethinking the role of opioids in the outpatient management of chronic nonmalignant pain. Curr Med Res Opin. 2014;30(10):2051–2062.
   PubMed Web of Science ®Google Scholar
• Els C, Jackson TD, Kunyk D, et al. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017;10:CD012509.
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Kaye AM, Knezevic NN, et al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician. 2017;20(2S):S3‐S92.
   Google Scholar
• Meske DS, Lawal OD, Elder H, et al. Efficacy of opioids versus placebo in chronic pain: a systematic review and meta-analysis of enriched enrolment randomized withdrawal trials. J Pain Res. 2018;11:923–934.
   PubMed Web of Science ®Google Scholar
• Faria J, Barbosa J, Moreira R, et al. Comparative pharmacology and toxicology of tramadol and tapentadol. Eur J Pain. 2018;22(5):827–844.
   PubMed Web of Science ®Google Scholar
• Morgan CL, Jenkins-Jones S, Currie C, et al. Outcomes associated with treatment of chronic pain with tapentadol compared with morphine and oxycodone: a UK primary care observational study. Adv Ther. 2019;36(6):1412–1425.
   Web of Science ®Google Scholar
• Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain. 2008;9:1144–1154.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhou JG, Zhang Y, et al. Opioid-induced constipation relief from fixed-ratio combination prolonged-release oxycodone/naloxone compared with oxycodone and morphine for chronic non-malignant pain: a systematic review and meta-analysis of randomized controlled trials. J Pain Symptom Manage. 2017;54(5):737–748.e3.
   PubMed Web of Science ®Google Scholar
• The Spanish Agency of Medicines and Medical Devices (AEMPS). Summary of Product Characteristics tapentadol (Palexia retard®, Grünenthal pharma, S.A). Available from: https://cima.aemps.es/cima/dochtml/ft/75917/FT_75917.html. Accessed May 20, 2019.
   Google Scholar
• The Spanish Agency of Medicines and Medical Devices (AEMPS). Summary of Product Characteristics oxycodone/naloxone (Targin®, Mundipharma pharmaceuticals, S.L.). Available from: https://cima.aemps.es/cima/dochtml/ft/71124/FT_71124.html. Accessed May 20, 2019.
   Google Scholar
• Viñas-Bastart M, Oms-Arias M, Pedraza-Gutiérrez À, et al. Clinical use of pregabalin in general practice in Catalonia, Spain: a population-based cross-sectional study. Pain Med. 2018;19:1639–1649.
   PubMed Web of Science ®Google Scholar
• Government of Catalonia. Department of Health. Organization Chart: unit of coordination and strategy of the medicine; 2019. Available from: http://www14.gencat.cat/sacgencat/AppJava/organigrama.jsp?codi=10137&jq=200001. Accessed December 20, 2020.
   Google Scholar
• Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo and active-controlled Phase III study. Clin Drug Investig. 2010;30:489–505.
   PubMed Web of Science ®Google Scholar
• Baron R, Jansen J-P, Binder A, et al. Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open- label, phase 3b/4 trial. Pain Pract. 2016;16(5):600–619.
   PubMed Web of Science ®Google Scholar
• D’Amato T, Martorelli F, Fenocchio G, et al. Tapentadol vs oxycodone/naloxone in the management of pain after total hip arthroplasty in the fast track setting: an observational study. J Exp Orthop. 2019;6(1):36.
   PubMedGoogle Scholar
• Anekar AA, Cascella M. WHO Analgesic Ladder.In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021.
   Google Scholar
• Zhang L, Losin EAR, Ashar YK, Koban L, Wager TD. Gender biases in estimation of others’ pain. J Pain. 2021. doi:10.1016/j.jpain.2021.03.001
   Web of Science ®Google Scholar
• Bartley EJ, Fillingim RB. Sex differences in pain: a brief review of clinical and experimental findings. Br J Anesth. 2013;111(1):52–58.
   PubMed Web of Science ®Google Scholar
• Packiasabapathy S, Sadhasivam S. Gender, genetics, and analgesia: understanding the differences in response to pain relief. J Pain Res. 2018;11:2729–2739.
   Web of Science ®Google Scholar
• O’Brien T, Christrup LL, Drewes AM, et al. European Pain Federation position paper on appropriate opioid use in chronic pain management. Eur J Pain. 2017;21(1):3–19.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Long-acting opioids for chronic non-cancer pain: a review of the clinical efficacy and safety; 2015. Available from: https://cadth.ca/sites/default/files/pdf/htis/aug-2015/RC0698%20Opioids%20Final.pdf. Accessed June 20, 2020.
   Google Scholar
• Agency for Healthcare Research and Quality (AHRQ). Opioid Treatments for Chronic Pain. Comparative Effectiveness Review No. 229. AHRQ Publication No. 20-EHC011; 2020. Available from: https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/opioids-chronic-pain.pdf. Accessed June 20, 2021.
   Google Scholar
• Johnston KJA, Ward J, Ray PR, et al. Sex-stratified genome-wide association study of multisite chronic pain in UK Biobank. PLoS Genet. 2021;17(4):e1009428.
   Web of Science ®Google Scholar
• Hadlandsmyth K, Mosher H, Lund BC. Associations between initial opioid exposure and the likelihood for long-term use. J Am Pharm Assoc. 2019;59(1):17–22.
   Google Scholar
• Bialas P, Maier C, Klose P, et al. Efficacy and harms of long-term opioid therapy in chronic non-cancer pain: systematic review and meta-analysis of open-label extension trials with a study duration ≥26 weeks. Eur J Pain. 2020;24:265–278.
   PubMed Web of Science ®Google Scholar
• Wong CK, O’Rielly CM, Teitge BD, et al. The characteristics and effectiveness of interventions for frequent emergency department utilizing patients with chronic noncancer pain: a systematic review. Acad Emerg Med. 2020;27(8):742–752.
   Web of Science ®Google Scholar